Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 1,861 INR
Change Today +18.30 / 0.99%
Volume 887.2K
As of 6:06 AM 11/24/15 All times are local (Market data is delayed by at least 15 minutes).

lupin ltd (LPC) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/6/15 - 2,129
52 Week Low
12/17/14 - 1,342
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for LUPIN LTD (LPC)

Related News

No related news articles were found.

lupin ltd (LPC) Related Businessweek News

No Related Businessweek News Found

lupin ltd (LPC) Details

Lupin Limited, a pharmaceutical company, produces, develops, and markets a range of branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. It offers formulations for use in the areas of cardiovascular, diabetology, asthma, pediatric, central nervous system (CNS), gastro-intestinal, anti-diabetic, anti-infective, NSAID, anti- tuberculosis, cephalosporin, gynaecology, and other therapeutic areas; and APIs for use in therapeutic areas of antibiotics, anti-tuberculosis, cardiovascular, CNS, analgesics, and anti-gout. The company also develops drug delivery technologies; and creates and develops biosimilars for various therapeutic indications, such as oncology, inflammation, antivirals, osteoporosis, rheumatoid arthritis, and ophthalmics. In addition, it engages in the novel drug discovery and development programs for use in the treatment of CNS disorders, oncology, immunology, pain and inflammation, infections, and metabolic/endocrine disorders. Lupin Limited has a strategic licensing agreement with InspiRX Inc. The company was formerly known as Lupin Chemicals Limited and changed its name to Lupin Limited in 2001 as a result of its amalgamation with Lupin Laboratories Limited. Lupin Limited was founded in 1968 and is headquartered in Mumbai, India.

15,000 Employees
Last Reported Date: 06/27/15
Founded in 1968

lupin ltd (LPC) Top Compensated Officers

Managing Director, Executive Director, Member...
Total Annual Compensation: 81.5M
Founder, Chairman, Chairman of Allotment Comm...
Total Annual Compensation: 36.7M
Chief Financial Officer, Director and Member ...
Total Annual Compensation: 79.2M
Vice Chairman, Chairman of Share Transfer Com...
Total Annual Compensation: 139.4M
Executive Director, Member of Share Transfer ...
Total Annual Compensation: 4.6M
Compensation as of Fiscal Year 2015.

lupin ltd (LPC) Key Developments

Lupin Limited Receives FDA Approvals for Generic Loestrin Fe 1/20 and Loestrin 1.5/30 Tablets

Lupin Limited announced that it has received final approvals for its Blisovi Fe 1/20 Tablets (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate Tablets, 75 mg) and Blisovi 1.5/30 Tablets (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1.5 mg/0.03 mg and Ferrous Fumarate Tablets, 75 mg) from the United States Food and Drug Administration (FDA) to market generic versions of Warner Chilcott's Loestrin Fe 1/20 Tablets (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate Tablets, 75 mg) and Loestrin Fe 1.5/30 Tablets (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1.5 mg/0.03 mg and Ferrous Fumarate Tablets, 75 mg). Lupin's US subsidiary, Lupin Pharmaceuticals Inc. shall commence promoting the product in the US shortly. Lupin's Blisovi Fe 1/20 Tablets and Blisovi 1.5/30 Tablets are the AB rated generic equivalent of Warner Chilcott's Loestrin Fe 1/20 Tablets and Loestrin Fe 1.5/30 Tablets and are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.

Vanda Pharmaceuticals Inc. Files Patent Infringement Lawsuit against Lupin Limited and Lupin Pharmaceuticals, Inc

On November 19, 2015, Vanda Pharmaceuticals Inc. filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Lupin Limited and Lupin Pharmaceuticals, Inc. The lawsuit seeks an adjudication that Lupin has infringed one or more claims of the company's U.S. Patent No. 9,138,432 (the 432 Patent) and U.S. Patent No. 8,586,610 (the 610 Patent) by submitting to the U.S. Food and Drug Administration an Abbreviated New Drug Application for a generic version of Fanapt prior to the expiration of the 432 Patent in September 2025 and the 610 Patent in November 2027. The relief requested by the Company in the lawsuit includes a request for a permanent injunction preventing Lupin from infringing the asserted claims of the 432 Patent and the 610 Patent by engaging in the manufacture, use, offer to sell, sale, importation or distribution of generic versions of Fanapt before their respective expiration dates.

Lupin Mulls Acquisitions

Lupin Limited (BSE:500257) is seeking acquisitions in Japan. Managing Director, Nilesh Gupta said: "We see tremendous potential in areas of central nervous system and cardiovascular drugs in Japan, and are keen for more acquisition."


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LPC:IN 1,860.90 INR +18.30

LPC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $74.06 USD -0.20
Cadila Healthcare Ltd 412.70 INR -11.25
Cipla Ltd/India 637.30 INR -4.15
Dr Reddy's Laboratories Ltd 3,388 INR -21.55
H Lundbeck A/S kr211.80 DKK +0.60
View Industry Companies

Industry Analysis


Industry Average

Valuation LPC Industry Range
Price/Earnings 39.9x
Price/Sales 6.5x
Price/Book -- Not Meaningful
Price/Cash Flow 33.0x
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact LUPIN LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at